MHRA alerts Ozempic and Wegovy users to rare but serious vision loss risk

Patients using these medications face risk of sudden vision loss requiring emergency treatment, though the condition is described as extremely rare.

Britain's medicines regulator has issued a safety alert for the 1.6 million UK users of semaglutide-based drugs — Ozempic, Wegovy, and Rybelsus — warning of an extremely rare but serious eye condition called NAION, which can cause sudden, painless vision loss in one eye. The MHRA's alert, arriving just days after a separate warning about acute pancreatitis risk from the same class of drugs, reflects the broader challenge of monitoring widely adopted medicines as their use scales across populations. Though the risk remains vanishingly small, the consequences are serious enough that regulators a

MHRA alerts Ozempic and Wegovy users to rare but serious vision loss risk

Cobertura Relacionada

Receba o Register no seu e-mail